Criteria for use of pancuronium bromide, vecuronium bromide, atracurium besylate, tubocurarine chloride, metocurine iodide, pipecuronium bromide, and doxacurium chloride in adults.
Donnelly
A J
AJ
Department of Pharmacy, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL.
Golembiewski
J A
JA
Skupski
R
R
Wojtynek
J E
JE
D015113:Androstane-3,17-diol / Q000008:administration & dosage / Q000031:analogs & derivatives; D001279:Atracurium / Q000008:administration & dosage; D004363:Drug Utilization; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000009:adverse effects; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage / Q000009:adverse effects; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage; D010197:Pancuronium / Q000008:administration & dosage; D017300:Pipecuronium; D010879:Piperazines / Q000008:administration & dosage; D014403:Tubocurarine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014673:Vecuronium Bromide / Q000008:administration & dosage
D007546:Isoquinolines; D009125:Muscle Relaxants, Central; D009466:Neuromuscular Blocking Agents; D003473:Neuromuscular Nondepolarizing Agents; D010879:Piperazines; D017300:Pipecuronium; D015113:Androstane-3,17-diol; D001279:Atracurium; D014673:Vecuronium Bromide; D010197:Pancuronium; C049429:doxacurium; C032943:metocurine; D014403:Tubocurarine